Health and Reproductive Performance of Lactating Dairy Cows with Mild Fatty Liver Receiving Exogenous Glucagon

Gerd Bobe
Iowa State University

Burim N. Ametaj
Iowa State University

Rafael A. Nafikov
Iowa State University

Donald C. Beitz
Iowa State University

Jerry W. Young
Iowa State University

Recommended Citation
Health and Reproductive Performance of Lactating Dairy Cows with Mild Fatty Liver Receiving Exogenous Glucagon

A. S. Leaflet R1904

Gerd Bobe¹, Research Associate, Burim N. Ametaj², Postdoctoral Research Associate, Rafael A. Nafikov, Graduate Research Assistant, Donald C. Beitz, Distinguished Professor of Agriculture, and Jerry W. Young³, Professor Emeritus

Summary and Implications
The data demonstrate that mild fatty liver is associated with decreased general health and reproductive performance as evidenced by more days to first estrus and service, more days open, decreased conception, increased number of days with elevated body temperature at days 9 - 22 postpartum, and increased incidence of mastitis at days 32 – 150 postpartum. The latter two were decreased in dairy cows with mild fatty liver injected with 15 mg/d of glucagon during weeks 2 and 3 postpartum. Therefore, treatment of mild fatty liver with exogenous glucagon or better prevention of fatty liver might improve health and reproductive performance of lactating dairy cows, thereby preventing loss of income of dairy farmers.

Introduction
Fatty liver is a metabolic disease that affects up to 50% of dairy cows in early lactation. Fatty liver is associated with an increased incidence and duration and decreased treatment success of infectious and metabolic diseases, such as mastitis, metritis, and ketosis, as well as decreased reproductive performance in affected cows. A major reason for this association is that hepatic lipid accumulation can impair liver function, such as synthesis and biotransformation of metabolites and proteins and the detoxification and excretion of toxic waste products and xenobiotics, which, in turn, can compromise immune competence and ovarian function.

A previous study from our group demonstrated that severe fatty liver and ketosis can be treated by continuous, intravenous infusions of 10 mg/d of glucagon for 14 days. In that study, cows were induced artificially into fatty liver and ketosis, however, by feed restriction and administration of 1,3-butanediol, and the effects on health and reproduction were not determined. The objectives of the current study was to determine whether a) mild fatty liver is associated with decreased health status (mastitis, elevated body temperature, and ketosis) and reproductive performance (days to first observed estrus, first service, days open, number of services, conception rate after first service, and overall conception rate) and b) whether glucagon injected subcutaneously at 7.5 or 15 mg/d for 14 days starting at day 8 postpartum could decrease some of the detrimental associations of mild fatty liver on health and reproductive performance.

Materials and Methods
For the experiment, 32 Holstein dairy cows were used that were 32 – 74 months of age, weighed 1190 – 1725 kg, had a body condition score of 3.00 – 4.25 on a 1 -5 scale, and had completed 1-4 lactations. For the last 4 weeks prepartum, each cow was offered individually, in addition to hay and the total mixed ration that was formulated to meet NRC requirements, 6 kg of cracked corn daily to potentially increase the incidence of mild fatty liver. All cows were visually healthy before parturition. At day 8 postpartum, cows were divided into two groups depending on their liver triacylglycerol concentrations (cutoff value of 1% liver wet weight) at day 8 postpartum. Cows with normal liver (n = 8; Saline Normal) and triacylglycerol concentrations <1% of liver wet weight were injected subcutaneously with 60 ml of 0.15 M NaCl every 8 hours (6:00, 14:00, and 22:00 for 14 days starting at 14:00 of day 8 postpartum. Cows with mild fatty liver (n = 24; 8 cows randomly assigned to each treatment group) and triacylglycerol concentrations of 1 - 10% of liver wet weight were injected with 0 (Saline Susceptible), 2.5 (7.5 mg/d), or 5 (15 mg/d) mg of lyophilized glucagon. All cows were managed and treated in accordance with guidelines established by the Iowa State University Committee on Animal Care.

Cows were monitored twice daily for flakes in the milk and once daily at 9:00 for body temperature and urinary acetoacetate concentrations. As an indicator of ketosis, Ketostix® strips (Bayer Corporation, Tarrytown, NY) were used. Mastitis was defined by flakes in the milk or a somatic cell count in milk of >1,000,000 per ml. Milk samples were analyzed for somatic cell count at two consecutive milking at days 3, 8 (before first injection of glucagon), 11, 15, 22 (before last injection), 25, 28, 36, and 43 postpartum by mid-infrared spectrophotometry (Milk-O-Scan 203; Foss Food Technology, Eden Prairie, MN).

Estrus behavior was monitored for 1 hour twice daily. The reproductive tract was examined by rectal palpation and

¹ Current address: Department of Food Science and Human Nutrition, Michigan State University, 3 GM Trout Building, East Lansing, MI 48824.
² Current address: Department of Microbiology and Immunology, Cornell University, C5-102 Veterinary Medical Center, Ithaca, NY 14853.
³ Current address: 73 Alton Park Lane, Franklin, TN 37069.
ultrasound by a veterinarian every 2 weeks beginning at 20
days postpartum. Cows that were at least 42 days
postpartum, were confirmed open, and had at least one
corpus luteum were injected subcutaneously with 5 ml of
Lutalyse® (50 mg/ml PGF₂α; Pharmacia & Upjohn,
Kalamazoo, MI) every 14 days until they showed signs of
estrus and then were inseminated. Cows that were at least 45
days postpartum were inseminated 12 hours after they
allowed mounting. Cows whose previous insemination
passed at least 35 days without further estrus were examined
for pregnancy by palpation and ultrasound.

Chi-square tests were used to compare treatment group
means of incidence rates for health status (mastitis, body
temperatures >39.5 °C, and urinary concentrations >40
mg/dl) and reproductive performance parameter (conception
rate after the first service, and overall conception rate). A t-
test was used to compare average lengths of time with body
temperatures >39.5 °C of treatment groups. Days to first
heat, days to first service, and days open were assumed
Weibull distributed, and treatment means were compared by
using a chi-square test.

Results and Discussion

The data demonstrate that non-treated mild fatty liver
was associated with increased incidence of mastitis from
days 23 – 150 postpartum (Table 1). Treatment of mild fatty
liver with subcutaneous injections of glucagon, in particular
at 15 mg/d, decreased the incidence of mastitis (Table 1).
The association of mild fatty liver with increased incidence
of mastitis from days 23 – 150 postpartum seems surprising
because, at days 23 – 42 postpartum, cows had normal liver
triacylglycerol concentrations. A possible reason for the
higher incidence of mastitis in cows with non-treated mild
fatty liver is that mild fatty liver might compromise the
immune response to mammary infections, which originated
from the peripartal period (Table 1). This possibility is
supported by the decreased number of days with elevated
body temperatures at 9 – 22 days postpartum of cows with
normal liver and cows with mild fatty liver receiving 15
mg/d of glucagon.

Cows with mild fatty liver had a decreased reproductive
performance (Table 2). The decreased reproductive
performance was associated with a higher incidence of
mastitis and a longer period of time in negative energy
balance. Five of the 6 cows that did not conceive had
mastitis at days 43 – 150 postpartum, whereas only 8 of the
24 cows that conceived had mastitis ($P \leq 0.03$). Fifteen of
the 22 cows with mild fatty liver that were inseminated had
a lower body weight at days 23 – 42 postpartum than at days
9 – 22, whereas the same was true for only 2 of 8 cows with
normal liver ($P \leq 0.03$). Mastitis and negative energy
balance both are associated with decreased signs of estrus,
conception rate, and embryo survival rates. Subcutaneous
injections of glucagon did not improve reproductive
performance of cows with mild fatty liver (Table 2). We
attribute the lack of positive effects of exogenous glucagon
on reproductive parameters to the fact that glucagon did not
decrease the length of time during which cows were in
negative energy balance. In another study from our group,
injections of 15 mg/d of glucagon for 14 days beginning at
day 2 postpartum prevented mild fatty liver. Therefore,
exogenous glucagon, given directly after calving for 14
days, might improve reproductive performance. Overall, the
results indicate that subcutaneous injections of 15 mg/d of
glucagon could alleviate some of the detrimental impacts of
mild fatty liver on health and reproduction and, therefore,
could improve overall performance and profitability of
lactating dairy cows.

Acknowledgments

The authors thank Swiss Valley Farms (Davenport,
IA) for analysis of milk samples and Eli Lilly (Indianapolis,
IN) for donation of glucagon. The research was supported
partly by grant number 99-35005-8576 from US
Department of Agriculture and was part of regional research
project NC-185. Appreciation is extended to the
management of the Iowa State University Dairy Teaching
Herd for provision of cows, to K. J. Koehler for assistance
in statistical analyses, and many undergraduate students for
assistance in collecting samples.
Table 1. Health status of cows with normal liver (Saline Normal) or mild fatty liver (Saline Susceptible, 7.5 mg/d Glucagon, 15 mg/d Glucagon) receiving either saline or glucagon at 7.5 or 15 mg/d or saline for 14 days beginning at day 8 postpartum

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Saline Normal (n = 8)</th>
<th>Saline Susceptible (n = 8)</th>
<th>7.5 mg/d Glucagon (n = 8)</th>
<th>15 mg/d Glucagon (n = 8)</th>
<th>C1</th>
<th>C2</th>
<th>C3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidences:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before injection period (days 0-8 postpartum):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Mastitis</td>
<td>4</td>
<td>5</td>
<td>4</td>
<td>6</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Body temp. &gt; 39.5°C</td>
<td>5</td>
<td>6</td>
<td>6</td>
<td>5</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Acetoac. &gt; 40 mg/d</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>4</td>
<td>NS</td>
<td>NS</td>
<td>0.02</td>
</tr>
<tr>
<td>During injection period (days 9-22 postpartum):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Mastitis</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Body temp. &gt; 39.5°C</td>
<td>8</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Acetoac. &gt; 40 mg/d</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>After injection period (days 23-42 postpartum):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.02</td>
<td>NS</td>
<td>0.02</td>
</tr>
<tr>
<td>Mastitis</td>
<td>0</td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>0.02</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Body temp. &gt; 39.5°C</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Acetoac. &gt; 40 mg/d</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>During insemination and conception period (days 43-150 postpartum):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.04</td>
<td>0.01</td>
<td>0.04</td>
</tr>
<tr>
<td>Mastitis</td>
<td>3</td>
<td>7</td>
<td>2</td>
<td>3</td>
<td>0.04</td>
<td>0.01</td>
<td>0.04</td>
</tr>
</tbody>
</table>

Time length: Days per week (mean ± SEM)

During injection period (days 9-22 postpartum):
| Body temp. > 39.5°C                | 2.0 ± 0.5 | 3.9 ± 0.6 | 3.0 ± 0.6 | 1.9 ± 0.5 | 0.02 | NS | 0.02 |
| After injection period (days 23-42 postpartum):
| Body temp. > 39.5°C                | 0.4 ± 0.7 | 0.5 ± 0.6 | 1.2 ± 0.5 | 0.9 ± 0.5 | NS | NS | NS |

C1: contrast between Saline Normal and Saline Susceptible (association with Susceptibility); C2: contrast between 7.5 mg/d Glucagon and Saline Susceptible (effect of 7.5 mg/d glucagon); C3: contrast between 15 mg/d Glucagon and Saline Susceptible (effect of 15 mg/d glucagon); NS = not significant at P > 0.05; urinary acetoacetate concentrations > 40 mg/dl.

Table 2. Reproductive health and performance of cows with normal liver (Saline Normal) or mild fatty liver (Saline Susceptible, 7.5 mg/d Glucagon, 15 mg/d Glucagon) receiving either saline or glucagon at 7.5 or 15 mg/d or saline for 14 days beginning at day 8 postpartum

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Saline Normal (n = 8)</th>
<th>Saline Susceptible (n = 8)</th>
<th>7.5 mg/d Glucagon (n = 7)</th>
<th>15 mg/d Glucagon (n = 7)</th>
<th>C1</th>
<th>C2</th>
<th>C3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reproduction:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First estrus</td>
<td>44 ± 5</td>
<td>54 ± 8</td>
<td>56 ± 6</td>
<td>51 ± 4</td>
<td>0.04</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>First service</td>
<td>53 ± 2</td>
<td>81 ± 12</td>
<td>74 ± 11</td>
<td>73 ± 10</td>
<td>0.003</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Days open</td>
<td>82 ± 24</td>
<td>105 ± 24</td>
<td>137 ± 17</td>
<td>104 ± 26</td>
<td>0.01</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Services (n/cow)</td>
<td>1.5 ± 0.4</td>
<td>2.6 ± 0.6</td>
<td>3.3 ± 0.7</td>
<td>2.7 ± 0.8</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Conception rate:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First service</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Overall</td>
<td>8</td>
<td>5</td>
<td>6</td>
<td>5</td>
<td>0.05</td>
<td>NS</td>
<td>NS</td>
</tr>
</tbody>
</table>

C1: contrast between Saline Normal and Saline Susceptible (association with Susceptibility); C2: contrast between 7.5 mg/d Glucagon and Saline Susceptible (effect of 7.5 mg/d glucagon); C3: contrast between 15 mg/d Glucagon and Saline Susceptible (effect of 15 mg/d glucagon); NS = not significant at P > 0.05.